This episode covers three ESMO trials. AZUR-1 supports organ preservation with dostarlimab in selected patients with mismatch repair deficient or microsatellite instability high rectal cancer. DeLLphi-305 found longer survival with tarlatamab plus durvalumab as maintenance treatment for extensive-stage small-cell lung cancer, with cytokine release syndrome requiring attention. TroFuse-005 found longer survival with sacituzumab tirumotecan than chemotherapy in previously treated advanced or recurrent endometrial cancer, with more severe treatment-related toxicity. The episode reviews the study populations, main results, and limits of each finding.